Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 8 von Hippel-Lindau Disease 3 Pheochromocytoma 2 Paraganglioma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Kidney Neoplasms 1 Hemangioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Fulvestrant 58 Trastuzumab 49 Capecitabine 47 Letrozole 45 pembrolizumab 41 Carboplatin 41 Paclitaxel 39 Cyclophosphamide 38 ribociclib 37 pertuzumab 36 abemaciclib 36 Blood Specimen Collection 31 trastuzumab deruxtecan 27 Specimen Handling 27 Docetaxel 27 Surveys and Questionnaires 26 Anastrozole 25 exemestane 24 Tamoxifen 24 palbociclib 21 130-nm albumin-bound paclitaxel 21 Magnetic Resonance Spectroscopy 19 sacituzumab govitecan 18 eribulin 18 Radiotherapy 18 Gemcitabine 18 Biopsy 18 olaparib 17 Injections 17 Epirubicin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Breast Neoplasms × belzutifan × Clear all

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡